Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

Trial Profile

Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs Adomeglivant (Primary)
  • Indications Diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PX-GRA
  • Most Recent Events

    • 21 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2017.
    • 27 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.
    • 02 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top